Drugs / SHR-2022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06131216 | Dec 2023 → Dec 2026 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06131216 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT06131216 ↗ |